Nippon Chemiphar
Tokyo, Japan· Est.
Japanese pharmaceutical company developing generics, allergy treatments, and novel drugs including a δ-opioid receptor agonist for depression.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese pharmaceutical company developing generics, allergy treatments, and novel drugs including a δ-opioid receptor agonist for depression.
Central Nervous SystemAllergy & ImmunologyOther (Generics)
Technology Platform
Proprietary alkalization therapy and core technologies in allergy research, applied to small molecule drug discovery and development.
Opportunities
Growth opportunities include successful development and commercialization of NC-2800 for depression, international expansion of its generic and proprietary product portfolios, and leveraging its alkalization therapy platform for additional novel drugs.
Risk Factors
Key risks include clinical trial failure of NC-2800, intense competition in generic and CNS markets, and execution challenges in global market expansion from its Japanese base.
Competitive Landscape
Competes with other Japanese generic manufacturers and CNS-focused biopharma companies; differentiation lies in its δ-opioid receptor agonist mechanism for depression and proprietary alkalization therapy platform.